Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578


Real-time Quote. Real-time Tradegate - 10/27 08:37:31 pm
69.57 EUR   +2.14%
07:02a SANOFI : Pasteur, Fiocruz, and WRAIR Agree to Collaborate on Zika Va..
10/25 SANOFI : - Sanofi : signs landmark agreement to combat antimicrobial..
10/25 GLOBAL DIABETIC : Nono Nordisk, Eli Llly, Sanofi, Merk, Tonghua Dong..
News SummaryMost relevantAll newsSector news 

Sanofi's Genzyme Says MS Drug Lemtrada Shows More Trial Success

share with twitter share with LinkedIn share with facebook
share via e-mail
04/24/2012 | 09:39pm CEST

Genzyme, the U.S. biotechnology unit of France's Sanofi SA (SNY), Tuesday said latest results from a late-stage clinical study showed its multiple sclerosis drug Lemtrada significantly reduced relapses and any worsening of the condition, and in some cases showed a reversal in disability.

In a Phase III trial called CARE-MS II involving 840 patients, the relapse rate was reduced by 49%, compared with an older drug called Rebif, or subcutaneous interferon beta-1a, which is sold by German rival Merck KGaA (>> Merck KGaA).

The company said 65% of patients treated with Lemtrada were relapse-free after two years into the study, compared with 47% treated with Rebif.

Genzyme is developing the drug, also known as alemtuzumab, in collaboration with German drug maker Bayer AG (>> Bayer AG), and Sanofi aims to launch the drug by the end of next year. Multiple sclerosis is a chronic disease that attacks the central nervous system.

"We believe these ground-breaking results from CARE-MS II, including reversal of disability accumulation in some patients, achieved over the standard therapy Rebif, provide a message of hope for people living with MS," said David Meeker, Genzyme's CEO, said in a statement, adding: "We are on track to submit alemtuzumab for review to U.S. and EU regulatory authorities in the second quarter of this year."

In the CARE-MS II trial, alemtuzumab was given as an injection eight times over the course of the two-year study. The first treatment course of alemtuzumab was administered on five consecutive days, and the second course was administered on three consecutive days 12 months later. Rebif was administered by injection three times per week, each week, throughout the two years of study.

Sanofi, which is struggling with patent expiries on its blockbuster drugs, bought Genzyme in February 2011 in a bid to widen its research net.

--By Sten Stovall, Dow Jones Newswires; +44 207 842 9292; sten.stovall@dowjones.com

Stocks mentioned in the article : Merck KGaA, Bayer AG
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on SANOFI
07:02a SANOFI : Pasteur, Fiocruz, and WRAIR Agree to Collaborate on Zika Vaccine Resear..
10/25 SANOFI : - Sanofi : signs landmark agreement to combat antimicrobial resistance
10/25 GLOBAL DIABETIC NEPHROPATHY (INSULIN : Nono Nordisk, Eli Llly, Sanofi, Merk, Ton..
10/25SANOFI SA : quaterly earnings release
10/21 SANOFI : Genzyme Assigned Patent
10/19 PROMIS NEUROSCIENCES : announces appointment of Dr. Richard Gregory to its Board..
10/18 GLOBAL MENINGOCOCCAL INFECTIONS VACC : Sanofi-Pasteur, Beijing Tiantan Biologica..
10/18 SCHNEIDER ELECTRIC : Three air france apprentices win prizes at altern'up
10/13 REGENERON PHARMACEUTICALS : and Sanofi Announce Positive Dupixent® dupilumab Pha..
10/13 SANOFI : Availability of the Pre-quarterly Results Communication
More news
Sector news : Pharmaceuticals - NEC
08:35pDJApple Unveils New Macs, TV App
07:25p ASTRAZENECA : pauses two cancer drug trials' enrolment due to bleeding
07:15pDJBRISTOL MYERS SQUIBB : Makes Moves to Reassure Investors
07:13pDJBRISTOL MYERS SQUIBB : Makes Moves to Reassure Investors
10/26 GLAXOSMITHKLINE : British imports of cheap medicines dry up as pound falls
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
06:59a WALL STREET BREAKFAST : Semiconductor Consolidation Continues
04:44a Sanofi accelerates Zika vaccine work
10/18 In Less Than A Month, Regeneron's Luck Kicks In
10/17 Tracking Ken Fisher's Fisher Asset Management Portfolio - Q3 2016 Update
10/14 WALL STREET BREAKFAST : Big Bank Earnings On Tap
Financials (€)
Sales 2016 36 665 M
EBIT 2016 9 178 M
Net income 2016 5 260 M
Debt 2016 5 715 M
Yield 2016 4,39%
P/E ratio 2016 15,37
P/E ratio 2017 14,17
EV / Sales 2016 2,55x
EV / Sales 2017 2,57x
Capitalization 87 802 M
More Financials
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Full-screen chart
Technical analysis trends SANOFI
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus HOLD
Number of Analysts 25
Average target price 81,3 €
Spread / Average Target 19%
Consensus details
EPS Revisions
More Estimates Revisions
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jérôme Contamine Chief Financial Officer & EVP-Finance
Elias E. Zerhouni President-Global Research & Development
Yong-Jun Liu Head-Global Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI-13.35%95 774
JOHNSON & JOHNSON11.53%313 422
ROCHE HOLDING LTD.-17.44%196 913
PFIZER INC.0.37%196 527
NOVARTIS AG-16.42%188 199
MERCK & CO., INC.15.24%168 318
More Results